Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing precision medicine therapeutics for serious oncology conditions with unmet medical needs. The company's lead program, NXP900, is a targeted small-molecule inhibitor of SRC and YES1 kinases licensed from the University of Edinburgh, designed to selectively inhibit both catalytic and scaffolding functions unlike existing kinase inhibitors, with potential applications across multiple solid tumors including breast, colon, prostate, pancreatic, and ovarian cancers. The company earns revenue through milestone payments and royalties on future product sales, relies on third-party manufacturers for drug development and production, and operates in a competitive landscape against larger pharmaceutical firms and other kinase inhibitor developers.